1 Nanomedicine, Department of Pharmacy, Faculty of Health and Medical Sciences, Københavns Universitet2 Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.3 Tarbiat Modares University4 National Cell Bank of Iran, Pasteur Institute of Iran5 Pasteur Institute of Iran6 Department of Pharmacy, Faculty of Pharmaceutical Sciences, Københavns Universitet7 Pasteur Institute of Iran8 Department of Pharmacy, Faculty of Pharmaceutical Sciences, Københavns Universitet
towards tumor-directed oligoclonal T cell therapy
Adoptive cell therapy with engineered T cells expressing chimeric antigen receptors (CARs) originated from antibodies is a promising strategy in cancer immunotherapy. Several unsuccessful trials, however, highlight the need for alternative conventional binding domains and the better combination of costimulatory endodomains for CAR construction to improve the effector functions of the engineered T cells. Camelid single-domain antibodies (VHHs), which are the smallest single domain antibodies, can endow great targeting ability to CAR-engineered T cells.
B B a - General Subjects, 2014, Vol 1840, Issue 1, p. 378-86